STZ-established DN in TLR4 knockout (TLR4−/−, KO) and wild-type (WT) mice treated orally with DMDD (at doses of 12.5, 25, and 50 mg/kg for 28 days) lowered serum TC, TG, HDL-C, and LDL-C, blood glucose content and kidney function markers, including Scr and BUN, significantly and increased the quantity and density of podocytes spectacularly, contributing to DN symptom alleviation. Here, TLR4 is linked to liver dysplastic nodule.